CD274 and melanoma: Historically, the clinical utility of PD-L1 expression assessment in melanoma has been regarded as controversial, considering the challenges associated with the interpretation of PD-L1 immunocolorations, the variability in the expression patterns of this biomarker and the role of other factors (such as tumor mutational burden, immune cell infiltration, and other immunological checkpoints) in immunotherapy response.